Endogenous angiogenesis inhibitors
Tóm tắt
When the FDA commissioner announced in February 2004 the approval of Avastin for the treatment of patients with colon cancer, he called angiogenesis inhibitors a fourth modality of anti‐cancer therapy. Because angiogenesis inhibitors are relatively less toxic than conventional chemotherapy and have a lower risk of drug resistance, they may also represent a new class of anti‐cancer agents, some of which have sufficiently reduced toxicity that they may be safely used long term. These include immunotherapy, vaccines, telomerase inhibitors, apoptosis inducers, low dose metronomic chemotherapy, novel hormonal therapies, gene therapy and others. However, at least 16
Từ khóa
Tài liệu tham khảo
Gimbrone MA, 1973, Endothelial regeneration: studies with human endothelial cells in culture, Ser Haematol, 6, 453
Folkman J, 2000, Cancer Medicine, 132
Folkman J, 2003, Cancer Medicine, 161
Folkman J, 1997, The Clinical Applications of the Interferons, 255
LeBlanc R, 2002, Proteasome inhibitor PS‐341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model, Cancer Res, 62, 4996
Nawrocki ST, 2002, Effects of the proteasome inhibitor PS‐341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts, Mol Cancer Ther, 1, 1243
Sunwoo JB, 2001, Novel proteasome inhibitor PS‐341 inhibits activation of nuclear factor‐kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma, Clin Cancer Res, 7, 1419
Ciardiello F, 2001, Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor, Clin Cancer Res, 7, 1459
Bruns CJ, 2000, Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma, Cancer Res, 60, 2926
Bertolini F, 2001, Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis, Analysis of clinical results and of surrogate angiogenesis markers. Ann Oncol, 12, 987
Relf M, 1997, Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta‐1, platelet‐derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis, Cancer Res, 57, 963
Browder T, 2000, Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug‐resistant cancer, Cancer Res, 60, 1878
Marx GM, 2002, Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock!, J Clin Oncol, 20, 1446, 10.1200/JCO.2002.20.6.1446
Wickstrom SA, 2002, Endostatin associates with integrin alpha 5 beta1 and caveolin‐1, and activates Src via a tyrosyl phosphatasedependent pathway in human endothelial cells, Cancer Res, 62, 5580
Lentzsch S, 2002, S‐3‐Amino‐phthalimido‐glutarimide inhibits angiogenesis and growth of B‐cell neoplasias in mice, Cancer Res, 62, 2300
Sidky YA, 1987, Inhibition of angiogenesis by interferons: effects on tumor‐ and lymphocyte‐induced vascular responses, Cancer Res, 47, 5155
Ravi R, 2000, Regulation of tumor angiogenesis by p53‐induced degradation of hypoxiainducible factor 1alpha, Genes Dev, 14, 34, 10.1101/gad.14.1.34
Zhang L, 2000, Wild‐type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression, Cancer Res, 60, 3655
Kisker O, 2001, Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model, Cancer Res, 61, 7669
Masferrer JL, 2000, Antiangiogenic and antitumor activities of cyclooxygenase‐2 inhibitors, Cancer Res, 60, 1306
RoyR WewerUM ZurakowskiD PoriesSE MosesMA.ADAM 12 cleaves ECM proteins: Correlation with cancer status and stage.J Biol ChemSep 2004; in press.
Klement G, 2004, Early tumor detection using platelet uptake of angiogenesis regulators, Blood, 104, abstract in pre, 10.1182/blood.V104.11.839.839
Colorado PC, 2000, Anti‐angiogenic cues from vascular basement membrane collagen, Cancer Res, 60, 2520